Genetic epidemiology of environmental toxicity and cancer susceptibility: Human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues

Drug Metabolism Reviews

Volumn 31, Issue 2, 1999, Pages 467-487

  Nebert, Daniel W ^a   Ingelman Sundberg, Magnus ^b   Daly, Ann K ^c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; AROMATIC HYDROCARBON RECEPTOR; COUMARIN 7 HYDROXYLASE; CYTOCHROME P450; DEBRISOQUINE 4 HYDROXYLASE; DIMETHYLNITROSAMINE DEMETHYLASE; DRUG METABOLIZING ENZYME; EPOXIDE HYDROLASE; ETHOXYRESORUFIN DEETHYLASE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; PHENACETIN O DEETHYLASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); S MEPHENYTOIN 4' HYDROXYLASE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

CANCER SUSCEPTIBILITY; CONFERENCE PAPER; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; NOMENCLATURE; PHARMACOGENETICS; STRUCTURAL GENE; TOXICITY;

CYTOCHROME P-450 ENZYME SYSTEM; ENVIRONMENTAL POLLUTANTS; HUMANS; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; RECEPTORS, ARYL HYDROCARBON; TERMINOLOGY;

EID: 0032959531     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-100101931     Document Type: Conference Paper

References (73)

1. U. Meyer, Genetic polymorphisms of drug metabolism, Fund. Clin. Pharmacol., 4, 595-615 (1990).
2. F. J. Gonzalez and J. R. Idle, Pharmacogenetic phenotyping and genotyping, present status and future potential, Clin. Pharmacokin. Concepts, 26, 59-70 (1994).
3. W. Kalow and L. Bertilsson, Interethnic factors affecting drug response, Adv. Drug Res., 23, 1-53 (1994).
4. D. W. Nebert, Pharmacogenetics: 65 candles on the cake, Pharmacogenetics, 7, 435-440 (1997).
5. C. B. Ambrosone, J. L. Freudenheim, S. Graham, J. R. Marshall, J. E. Vena, J. R. Brasure, A. M. Michalek, R. Laughlin, T. Nemoto, K. A. Gillenwater, A. M. Harrington, and P. G. Shields, Cigarette smoking, N-acetyltransferase-2 genetic polymorphisms, and breast cancer risk, J. Am. Med. Assoc., 276, 1494-1501 (1996).
6. D. W. Nebert, R. A. McKinnon, and A. Puga, Human drug-metabolizing enzyme polymorphisms: Effects on risk of toxicity and cancer, DNA Cell Biol., 15, 273-280 (1996).
7. D. W. Nebert, Growth signal pathways, Nature, 347, 709-710 (1990).
8. D. W. Nebert, Proposed role of drug-metabolizing enzymes: Regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions, Mol. Endocrinol., 5, 1203-1214 (1991).
9. D. W. Nebert, Drug-metabolizing enzymes in ligand-modulated transcription, Biochem. Pharmacol., 47, 25-37 (1994).
10. D. W. Nebert, Polymorphisms in drug-metabolizing enzymes: What is their clinical significance and why do they exist? Am. J. Hum. Genet., 60, 265-271 (1997).
11. D. W. Nebert and F. J. Gonzalez, P450 genes: Structure, evolution and regulation, Annu. Rev. Biochem., 56, 945-993 (1987).
12. J. A. White, P. J. McAlpine, S. Antonarakis, H. Cann, J. T. Eppig, K. Frazer, J. Frezal, D. Lancet, J. Nahmias, P. Pearson, J. Peters, A. Scott, H. Scott, N. Spurr, C. Talbot, Jr., and S. Povey, Guidelines for human gene nomenclature (1997), Genomics, 45, 468-471 (1997).
13. S. E. Antonarakis, et al. (30 other coauthors), Recommendations for a nomenclature system for human gene mutations, Hum. Mutat., 11, 1-3 (1998).
14. A. J. Schafer and J. R. Hawkins, DNA variation and the future of human genetics, Nature Biotechnol., 16, 33-39 (1998).
15. D. Marez, M. Legrand, N. Sabbagh, J. M. L. Guidice, C. Spire, J. J. Lafitte, U. A. Meyer, and F. Broly, Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution, Pharmacogenetics, 7, 193-202 (1997).
16. Y. Hu, M. Oscarson, I. Johansson, Q. Y. Yue, M. L. Dahl, M. Tabone, S. Arinco, E. Albano, and M. Ingelman-Sundberg, Genetic polymorphism of human CYP2E1: Characterization of two variant alleles, Mol. Pharmacol., 51, 370-376 (1997).
17. K. S. Fairbrother, J. Grove, I. de Waziers, D. T. Steimel, C. P. Day, C. L. Crespi, and A. K. Daly, Detection and characterization of novel polymorphisms in the CYP2E1 gene, Pharmacogenetics, 8, 543-552 (1998).
18. I. Cascorbi, J. Brockmöller, and I. Roots, A C4887A polymorphism in exon 7 of human CYP1A1: Population frequency, mutation linkages, and the impact to lung cancer susceptibility, Cancer Res., 56, 4965-4969 (1996).
19. A. Hildesheim, L. M. Anderson, C. J. Chen, Y. J. Cheng, L. A. Brinton, A. K. Daly, C. D. Reed, I. H. Chen, N. E. Caporaso, M. M. Hsu, J. Y. Chen, J. R. Idle, R. N. Hoover, C. S. Yang, and S. K. Chhabra, CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan, J. Natl. Cancer Inst., 89, 1207-1212 (1997).
20. C. Y. Chang and A. Puga, Constitutive activation of the aromatic hydrocarbon receptor, Mol. Cell Biol., 18, 525-535 (1998).
21. 1450 cDNA probe, Cytogenet. Cell Genet., 46, 574-575 (1987).
22. S. I. Hayashi, J. Watanabe, K. Nakachi, and K. Kawajiri, Genetic linkage of lung cancer-associated Msp I polymorphisms with amino acid replacement in the heme-binding region of the human cytochrome P450IA1 gene, J. Biochem. (Tokyo), 110, 407-411 (1991).
23. P. J. Wedlund, S. Kimura, F. J. Gonzalez, and D. W. Nebert, I462V mutation in the human CYP1A1 gene: Lack of correlation with either the Msp I (M2) allele or CYP1A1 inducibility in a 3-generation family of East Mediterranean descent, Pharmacogenetics, 4, 21-26 (1994).
24. I. Persson, I. Johansson, and M. Ingelman-Sundberg, In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility, Biochem. Biophys. Res. Commun., 231, 227-230 (1997).
25. F. Crofts, G. N. Cosma, D. Currie, E. Taioli, P. Toniolo, and S. J. Garte, A novel CYP1A1 gene polymorphism in African-Americans, Carcinogenesis, 14, 1729-1731 (1993).
26. K. Kawajiri, K. Nakachi, K. Imai, A. Yoshii, N. Shinoda, and I. Watanabe, Identification of genetically high risk individuals to lung cancer by polymorphisms of the cytochrome P4501A1 gene, FEBS Lett., 263, 131-133 (1990).
27. S. Hayashi, J. Watanabe, and K. Kawajiri, High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and mu-class glutathione S-transferase genes, Jpn. J. Cancer Res., 83, 866-870 (1992).
28. D. L. Eaton, E. P. Gallagher, T. K. Bammler, and K. L. Kunze, Role of cytochrome P450 1A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity, Pharmacogenetics, 5, 259-274 (1995).
29. T. Aoyama, K. Korzekwa, K. Nagata, J. R. Gillette, H. V. Gelboin, and F. J. Gonzalez, Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s, Endocrinology, 126, 3101-3106 (1990).
30. P. R. Sinclair, N. Gorman, T. Dalton, H. S. Walton, W. J. Bement, J. F. Sinclair, A. G. Smith, and D. W. Nebert, Uroporphyria produced in mice by iron and 5-aminolevulinic acid does not occur in Cyp1a2(-/-) null mutant mice, Biochem. J., 330, 149-153 (1998).
31. T. Shimada, C. H. Yun, Y. Hiroshi, J. C. Gautier, P. H. Beaune, and F. P. Guengerich, Characterization of human lung microsomal cytochrome P4501A1 and its role in the oxidation of chemical carcinogens, Mol. Pharmacol., 41, 856-864 (1992).
32. H. I. Swanson and C. A. Bradfield, The AH receptor: genetics, structure and function, Pharmacogenetics, 3, 213-230 (1993).
33. M. E. Hahn, S. I. Karchner, M. A. Shapiro, and S. A. Perera, Molecular evolution of two vertebrate aryl hydrocarbon (dioxin) receptors (AHR1 and AHR2) and the PAS family, Proc. Natl. Acad. Sci. USA, 94, 13743-13748 (1998).
34. J. A. Powell-Coffman, C. A. Bradfield, and W. B. Wood, Caenorhabditis elegans orthologs of the aryl hydrocarbon receptor and its heterodimerization partner the aryl hydrocarbon receptor nuclear translocator, Proc. Natl. Acad. Sci. USA, 95, 2844-2849 (1998).
35. D. W. Nebert, The Ah locus: Genetic differences in toxicity, cancer, mutation, and birth defects, CRC Crit. Rev. Toxicol., 20, 153-174 (1989).
36. D. W. Nebert, D. D. Petersen, and A. Puga, Human AH locus polymorphism and cancer: Inducibility of CYP1A1 and other genes by combustion products and dioxin, Pharmacogenetics, 1, 68-78 (1991).
37. M. Ema, N. Ohe, M. Suzuki, J. Mimura, K. Sogawa, S. Ikawa, and Y. Fujii-Kuriyama, Dioxin-binding activities of polymorphic forms of mouse and human aryl hydrocarbon receptors, J. Biol. Chem., 269, 27337-27343 (1994).
38. A. Poland, D. Palen, and E. Glover, Analysis of the four alleles of the murine aryl hydrocarbon receptor, Mol. Pharmacol., 46, 915-921 (1994).
39. A. B. Okey, D. K. Manchester, M. M. Feeley, D. L. Grant, and A. Gilman, Ah receptor characterization in human placenta samples, Organohalogen Compounds, 25, 177-184 (1995).
40. K. Kawajiri, J. Watanabe, H. Eguchi, K. Nakachi, C. Kiyohara, and S. Hayashi, Polymorphisms of human Ah receptor gene are not involved in lung cancer, Pharmacogenetics, 5, 151-158 (1995).
41. A. Maier, J. Micka, K. Miller, T. Denko, C. Y. Chang, D. W. Nebert, and A. Puga, Aromatic hydrocarbon receptor (AHR) polymorphism: Development of new methods to correlate genotype with phenotype, Environ. Health Perspect., 106, 421-426 (1998).
42. P. Fernandez-Salguero, S. M. G. Hoffman, S. Cholerton, H. Mohrenweiser, H. Raunio, A. Rautio, O. Pelkonen, J. D. Huang, W. E. Evans, J. R. Idle, and F. J. Gonzalez, A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles, Am. J. Hum. Genet., 57, 651-660 (1995).
43. G. C. Ibeanu, J. Blaisdell, B. I. Ghanayem, C. Beyeler, S. Benhamou, C. Bouchardy, G. R. Wilkinson, P. Dayer, A. K. Daly, and J. A. Goldstein, An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians, Pharmacogenetics, 8, 129-135 (1998).
44. A. Llerena, G. Edman, J. Cobaleda, J. Benítez, D. Schalling, and L. Bertilsson, Relationship between personality and debrisoquine hydroxylation capacity, Acta Psychiatr. Scand., 87, 23-28 (1993).
45. E. M. Sellers, S. V. Otton, R. F. Tyndale, R. S. Rapaka, N. Chiang, and B. R. Martin (eds.), The Potential Role of the Cytochrome P-450 2D6 Pharmacokinetic Polymorphism in Drug Abuse, NIDA Research Monograph Series, Department of Health and Human Services, Rockville, MD, 1997, pp. 6-173.
46. C. Sachse, J. Brockmöller, S. Bauer, and I. Roots, Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences, Am. J. Hum. Genet., 60, 284-295 (1997).
47. R. A. McLellan, M. Oscarson, J. Seidegård, D. A. P. Evans, and M. Ingelman-Sundberg, Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians, Pharmacogenetics, 7, 187-191 (1997).
48. A. K. Daly, J. Brockmöller, F. Broly, M. Eichelbaum, W. E. Evans, F. J. Gonzalez, J. D. Huang, J. R. Idle, M. Ingelman-Sundberg, T. Ishizaki, E. Jacqz-Aigrain, U. A. Meyer, D. W. Nebert, V. M. Steen, C. R. Wolf, and U. M. Zanger, Nomenclature for human CYP2D6 alleles, Pharmacogenetics, 6, 193-201 (1996).
49. K. P. Vatsis, W. W. Weber, D. A. Bell, J. M. Dupret, D. A. Price-Evans, D. M. Grant, D. W. Hein, H. J. Lin, U. A. Meyer, M. V. Relling, E. Sim, T. Suzuki, and Y. Yamazoe, Nomenclature for N-acetyltransferases, Pharmacogenetics, 5, 1-17 (1995).
50. M. A. Doll, W. Jiang, A. C. Deitz, T. D. Rustan, and D. W. Hein, Identification of a novel allele at the human NAT1 acetyltransferase locus, Biochem. Biophys. Res. Commun., 233, 584-591 (1997).
51. N. C. Hughes, S. A. Janezic, K. L. McQueen, M. A. S. Jewett, T. Castranio, D. A. Bell, and D. M. Grant, Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe, Pharmacogenetics, 8, 55-66 (1998).
52. 560A mutations, Pharmacogenetics, 8, 67-72 (1998).
53. D. Otterness, C. Szumlanski, L. Lennard, B. Klemetsdal, J. Aarbakke, J. O. Park-Hah, H. Iven, K. Schmiegelow, E. Branum, J. O'Brien, and R. Weinshilboum, Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms, Clin. Pharmacol. Ther., 62, 60-73 (1997).
54. P. I. Mackenzie, I. S. Owens, B. Burchell, K. W. Bock, A. Bairoch, A. Bélanger, S. Fournel-Gigleux, M. Green, D. W. Hum, T. Iyanagi, D. Lancet, P. Louisot, J. Magdalou, J. Roy Chowdhury, J. K. Ritter, H. Schachter, T. R. Tephly, K. F. Tipton, and D. W. Nebert, The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence, Pharmacogenetics, 7, 255-269 (1997).
55. T. J. Monks, M. W. Anders, W. Dekant, J. L. Stevens, S. S. Lau, and P. J. van Bladeren, Glutathione conjugate-mediated toxicities, Toxicol. Appl. Pharmacol., 106, 1-19 (1990).
56. J. Seidegård, R. W. Pero, D. G. Miller, and E. J. Beattie, A glutathione transferase in human lymphocytes as a marker for the susceptibility to lung cancer, Carcinogenesis, 7, 751-753 (1986).
57. E. Hallier, K. R. Schröder, K. Asmuth, A. Dommermuth, B. Aust, and H. W. Goergens, Metabolism of dichloromethane (methylene chloride) to formaldehyde in human erythrocytes: Influence of glutathione transferase theta (GST T1-1), Arch. Toxicol., 68, 423-427 (1994).
58. J. D. Hayes and D. J. Pulford, The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance, Crit. Rev. Biochem. Mol. Biol., 30, 445-600 (1995).
59. M. A. Watson, R. K. Stewart, G. B. Smith, T. E. Massey, D. A. Bell, Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution, Carcinogenesis, 19, 275-280 (1998).
60. R. A. McLellan, M. Oscarsson, A. K. Alexandrie, I. Seidegård, D. A. P. Evans, A. Rannug, and M. Ingelman-Sundberg, Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity, Mol. Pharmacol, 52, 958-965 (1997).
61. C. J. Henderson, A. G. Smith, J. Ure, K. Brown, E. J. Bacon, and C. R. Wolf, Increased skin tumorigenesis in mice lacking π class glutathione S-transferases, Proc. Natl. Acad. Sci. USA, 95, 5275-5280 (1998).
62. D. Ross, Quinone reductases, in: Comprehensive Toxicology (F. P. Guengerich, ed.), Elsevier Science, Oxford, 1998, Vol. 3, pp. 179-197.
63. W. A. Schulz, A. Krummeck, I. Rösinger, P. Eickelmann, C. Neuhaus, T. Ebert, B. J. Schmitz-Dräger, and H. Sies, Increased frequency of a nullellele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies, Pharmacogenetics, 7, 235-239 (1997).
64. 609C → T mutation and rapid fractional excretion of chlorzoxazone, Cancer Res., 57, 2839-2842 (1997).
65. J. K. Beetham, D. Grant, M. Arand, J. Garbarino, T. Kiyosue, F. Pinto, F. Oesch, W. R. Belknap, K. Shinozaki, and B. D. Hammock, Gene evolution of epoxide hydrolases and recommended nomenclature, DNA Cell Biol., 14, 61-71 (1995).
66. C. Hassett, L. Aicher, J. S. Sidhu, and C. J. Omiecinski, Human microsomal epoxide hydrolase: Genetic polymorphism and functional expression in vitro of amino acid variants, Hum. Mol. Genet., 3, 421-428 (1994).
67. J. M. Lancaster, H. A. Brownlee, D. A. Bell, P. A. Futreal, J. R. Marks, A. Berchuck, R. W. Wiseman, and J. A. Taylor, Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer, Mol. Carcinogen., 17, 160-162 (1996).
68. 1, Proc. Natl. Acad. Sci. USA, 92, 2384-2387 (1995).
69. F. J. Gonzalez and D. W. Nebert, Evolution of the P450 gene superfamily animal-plant "warfare," molecular drive, and human genetic differences in drug oxidation, Trends Genet., 6, 182-186 (1990).
70. V. De Laurenzi, G. R. Rogers, D. J. Hamrock, L. N. Marekov, P. M. Steinert, J. G. Compton, N. Markova, and W. B. Rizzo, Sjögren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene, Nature Genet., 12, 52-57 (1996).
71. I. Stoilov, A. N. Akarsu, and M. Sarfarazi, Identification of three different truncating mutations in cytochrome P450 1B1 (CYP1B1) as the principal cause of primary congenital glaucoma (buphthalmos) in families linked to the GLC3A locus on chromosome 2p21, Hum. Mol. Genet., 6, 641-647 (1997).
72. J. M. L. de Vree, E. Jacquemin, E. Sturm, D. Cresteil, P. J. Bosma, J. Aten, J. F. Deleuze, M. Desrochers, M. Burdelski, O. Bernard, R. P. J. Oude Elferink, and M. Hadchouel, Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis, Proc. Natl. Acad. Sci. USA, 95, 282-287 (1998).
73. D. W. Nebert and R. A. McKinnon, Cytochrome P450: Evolution and functional diversity, Prog. Liv. Dis., 12, 63-97 (1994).